Please login first
Anticancer Hybrid Combinations with phenolic compounds
* 1, 2 , * 1 , 2, 3 , 3
1  Department of Biomedical Sciences, Faculty of Pharmacy, University of Alcalá, Alcalá de Henares, Madrid, Spain.
2  Research Center for Biosciences & Health Technologies (CBIOS), Universidade Lusófona de Humanidades e Tecnologias, Campo Grande 376, 1749-024 Lisbon, Portugal
3  iMed.ULisboa - Research Institute for Medicines, Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal

Published: 30 October 2019 by MDPI in 5th International Electronic Conference on Medicinal Chemistry session Posters

Different types of treatments are being employed to overcome cancer, which is characterized by abnormal cell growth involving cell division without control. However, their usually lack of selectivity and the development of resistance result in limited efficacy or ineffectiveness of the therapies. For these reasons, seeking new treatment options for this disease is necessary. Nowadays, the acknowledge bioactive properties of some secondary metabolites such as polyphenols, have made antitumour hybrid combinations a promising therapeutic approach.

This work aims to provide a synopsis into Anticancer Hybrid Combinations involving phenolic compounds, focusing on their multi-target mechanisms of action and synergistic effects.

These combinations consist on the therapeutic mixture of synthetic drugs with chemically defined constituents from plants (secondary metabolites, in this case, phenolic compounds) aiming to increase the pharmacological activity of the formulation and simultaneously reduce the toxic side-effects of the drugs, interaction known as synergy.

Antitumour hybrid combinations are a promising therapeutic strategy to minimize adverse effects and to reduce cancer resistance to different treatments. At the same time, it shows selectivity to tumour cells and potentiate the activity of the drug that make them an interesting option to cure cancer.

[1] Domínguez-Martin EM, Diaz-Lanza AM, Faustino CMC (2018) Curr Pharm Des 24, 4312-4333.
[2] Wagner H, Efferth T. (2017) Phytomedicine, 37, 1-3.
[3] Mahbub AA, Le Maitre CL, Haywood-Small S, Cross NA, Nicola Jordan-Mahy N (2019) Oncotarget 10, 4570-86
[4] Zhong C, Qiu S, Li J, Shen J, Zu Y, Shi J, Sui G (2019) Phytomedicine 59, 152921

Keywords: Hybrid combinations, combination therapy, synergy, cancer, multicomponent, multi-target.